secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001193125-22-142297
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M
--------------------------------------------------------------------------------

- Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.
- Net loss improved to $12.3M ($0.07/shr) vs $17.5M ($0.10/shr) a year ago.
- Non-GAAP Adjusted EBITDA improved to -$3.7M from -$11.5M year-over-year.
- Signed multi-year INTERCEPT platelet contract with American Red Cross and 10-year Fresenius Kabi manufacturing extension.
- Cash and investments $108.6M at March 31, 2022; net cash used in operations $21.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/0001193125-22-142297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/d667280d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-142297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer